Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions-Reference-Cited by-同舟云学术

Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions

Published:2019-11 Issue:11 Volume:22 Page:1275-1282
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Vreman Rick A.,Heikkinen Inkatuuli,Schuurman Ad,Sapede Claudine,Garcia Jordi Llinares,Hedberg Niklas,Athanasiou Dimitrios,Grueger Jens,Leufkens Hubert G.M.,Goettsch Wim G.

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference23 articles.

1. Adaptive licensing: taking the next step in the evolution of drug approval;Eichler;Clin Pharmacol Ther,2012

2. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients;Eichler;Clin Pharmacol Ther,2015

3. Adaptive pathways: possible next steps for payers in preparation for their potential implementation;Vella Bonanno;Front Pharmacol,2017

4. Payers’ views of the changes arising through the possible adoption of adaptive pathways;Ermisch;Front Pharmacol,2016

5. Weighing of evidence by health technology assessment bodies: retrospective study of reimbursement recommendations for conditionally approved drugs;Vreman;Clin Pharmacol Ther,2019

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Variations in Unmet Health Care Needs by Perceptions of Social Media Health Mis- and Disinformation, Frequency of Social Media Use, Medical Trust, and Medical Care Discrimination: Cross-Sectional Study;JMIR Public Health and Surveillance;2024-07-11

2. Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned;Drug Discovery Today;2024-07

3. Balancing ethical norms and duties for the introduction of new medicines through conditional marketing authorization: a research agenda;Frontiers in Medicine;2024-06-24

4. Strategic aspects for the commercialization of nanomedicines;Journal of Controlled Release;2024-05

5. The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report;Clinical Pharmacology & Therapeutics;2024-04-28